Zuclopenthixol versus placebo for schizophrenia.

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Zuclopenthixol is an established antipsychotic with three formulations: dihydrochloride, acetate, and decanoate.
• Despite its long-term use, a systematic review comparing its efficacy against placebo in schizophrenia has been lacking.

Purpose of the Study:

• To systematically review the effectiveness of all zuclopenthixol formulations versus placebo for schizophrenia treatment.

Main Methods:

• Conducted a comprehensive search of multiple databases and clinical trial registries up to October 2015.
• Included randomized controlled trials comparing any zuclopenthixol formulation with placebo in schizophrenia patients.
• Extracted and analyzed data, assessing risk of bias and using GRADE methodology.

Main Results:

• Only two low-quality studies (65 participants) from 1968-1972 met inclusion criteria, focusing solely on zuclopenthixol dihydrochloride.
• Zuclopenthixol dihydrochloride showed a statistically significant improvement in global state when assessed by nurses (RR 2.57, 95% CI 1.06 to 6.20), but not psychiatrists.
• Increased sedation was observed with zuclopenthixol dihydrochloride (RR 4.67, 95% CI 1.23 to 17.68); data on relapse, mental state, and other outcomes were unavailable.

Conclusions:

• Zuclopenthixol dihydrochloride may offer symptom relief in schizophrenia, supported by limited, very low-quality evidence.
• Significant sedation and potential adverse effects are associated with zuclopenthixol dihydrochloride.
• No data exist for zuclopenthixol acetate or decanoate, highlighting a critical gap in evidence for commonly used antipsychotic formulations.